Literature DB >> 8781347

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.

R Ling1, D Mutimer, M Ahmed, E H Boxall, E Elias, G M Dusheiko, T J Harrison.   

Abstract

We describe mutations in the hepatitis B virus (HBV) polymerase gene in viruses which reactivated in two patients during therapy with -2'-deoxy-3'-thiacytidine, or lamivudine (3TC), and following orthotopic liver transplantation for chronic hepatitis B. Virus resistance to 3TC is associated with mutations which lead to amino acid substitutions in the highly conserved tyr-met-asp-asp (YMDD) motif, part of the active site of the polymerase, and which parallel those seen in resistant human immunodeficiency virus (HIV). Substitutions of valine and isoleucine for methionine were found in the two cases. The significance of single secondary mutations, which differ between viruses from the two patients, remains to be determined. Thus, viral resistance to lamivudine of hepatitis B virus mimics that of HIV and can occur in the setting of immunosuppression after liver transplantations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781347     DOI: 10.1002/hep.510240339

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  76 in total

1.  Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection?

Authors:  D Mutimer
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.

Authors:  T Zhou; J Saputelli; C E Aldrich; M Deslauriers; L D Condreay; W S Mason
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy.

Authors:  W N Chen; C J Oon
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 4.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

5.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 6.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

7.  Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.

Authors:  L Stuyver; C Van Geyt; S De Gendt; G Van Reybroeck; F Zoulim; G Leroux-Roels; R Rossau
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

8.  Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.

Authors:  Reiichiro Kuwahara; Ryukichi Kumashiro; Hiroto Inoue; Ryo Tanabe; Eisuke Tanaka; Teruko Hino; Tatsuya Ide; Yuriko Koga; Michio Sata
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 9.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

10.  Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.

Authors:  Suzane Kioko Ono-Nita; Naoya Kato; Yasushi Shiratori; Flair José Carrilho; Masao Omata
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.